Physician profile
David Corteville
NPI 1699867788
$87,265.04
in general payments reported to CMS, 2019-2025
28 companies · $34K in 2025
The $34K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $54.80 · 2021: $276 · 2022: $16K · 2023: $7,964 · 2024: $29K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $53K · Travel and Lodging: $9,735 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000 · Food and Beverage: $3,364 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $52,596.01 |
| Travel and Lodging | $9,734.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
| Food and Beverage | $3,363.82 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $70,746.22 | 2022-2025 | Ultomiris |
| Boston Scientific Corporation | $5,402.91 | 2025 | Watchman, Farapulse |
| Edwards Lifesciences Corporation | $4,398.13 | 2024-2025 | Evoque |
| Novartis Pharmaceuticals Corporation | $2,049.12 | 2019-2025 | |
| Abbott Laboratories | $1,918.27 | 2025 | Triclip |
| Astrazeneca Pharmaceuticals LP | $702.29 | 2019-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $459.26 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.95 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $199.12 | 2022-2024 | Mounjaro |
| Siemens Medical Solutions USA, INC. | $137.93 | 2019 | |
| Scpharmaceuticals INC. | $122.38 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $104.96 | 2019-2024 | Camzyos |
| Amgen INC. | $93.06 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $73.48 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $61.44 | 2023-2025 | Verquvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $54.70 | 2024 | Assure Wcd |
| Lantheus Medical Imaging, INC. | $42.31 | 2020-2023 | Definity |
| Astellas Pharma US INC | $37.74 | 2021-2022 | |
| Irhythm Technologies, INC. | $37.27 | 2022-2023 | Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $28.89 | 2025 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.34 | 2019 | |
| Pfizer INC. | $24.12 | 2023 | |
| Bracco Diagnostics INC. | $23.63 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $20.40 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $19.21 | 2024 | |
| Bridgebio Pharma, INC. | $13.89 | 2025 | Attruby |
| Sunovion Pharmaceuticals INC. | $11.02 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Corteville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.